Article
Nifuroxazide as JAK2 inhibitor: A binding mode proposal and Hel cell proliferation assay.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences - 1 Jul 2021
da Costa Marcela Oliveira Legramanti, Pavani Thais Fernanda Amorim, Lima Angélica Nakagawa, Scott Ana Lígia, Ramos Débora Felicia Vieira, Lazarini Mariana, Rando Daniela Gonçales Galasse
Abstract excerpt
Nifuroxazide has been employed as an anti-diarrheic agent since 1966, but in the last decade has brought to the research spotlight again due to its recently described antitumoral activity through the JAK2 inhibitory potential. Since 2008, more than 70 papers have been published about the issue and more are expected to the following years. Herein we discuss the findings of molecular modelling studies which were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.